Fig. 1: Design of ELI-002 2P, Amph mechanism of action and study participant disposition. | Nature Medicine

Fig. 1: Design of ELI-002 2P, Amph mechanism of action and study participant disposition.

From: Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Fig. 1

a, Schematic for ELI-002 2P vaccine components, including Amph-mKRAS G12D and G12R long peptide antigens and Amph-CpG-7909 TLR9 agonist. PEG, polyethylene glycol. b, Stepwise schematic for Amph-directed lymph-node-targeted biodistribution mechanism using albumin ‘hitchhiking’: (1) subcutaneous Amph injection, followed by (2) lipid-mediated non-covalent molecular association of Amph vaccines with tissue-resident endogenous albumin, resulting in (3) preferential absorption into lymphatics and accumulation through afferent lymph flow into draining lymph nodes and, finally, (4) uptake of Amph vaccines by lymph-node-resident APCs to induce antigen presentation and coordinated co-stimulation of cognate T cells. c, CONSORT diagram. Patients were enrolled into five successive cohorts with progressively increasing doses of Amph-CpG-7909 with a fixed dose of Amph-Peptides 2P. Graphical elements from a and b were adapted from previous publications under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) (refs. 57,58).

Back to article page